Literature DB >> 31792983

Synthesis and structure-activity relationships of teixobactin.

John A Karas1, Fan Chen1, Elena K Schneider-Futschik1,2, Zhisen Kang1, Maytham Hussein1, James Swarbrick1, Daniel Hoyer1,3,4, Andrew M Giltrap5, Richard J Payne5, Jian Li6, Tony Velkov1.   

Abstract

The discovery of antibiotics has led to the effective treatment of bacterial infections that were otherwise fatal and has had a transformative effect on modern medicine. Teixobactin is an unusual depsipeptide natural product that was recently discovered from a previously unculturable soil bacterium and found to possess potent antibacterial activity against several Gram positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci. One of the key features of teixobactin as an antibiotic lead is that resistance could not be generated in a laboratory setting. This is proposed to be a result of a mechanism of action that involves binding to essential cell wall synthesis building blocks, lipid II and lipid III. Since the initial isolation report in 2015, significant efforts have been made to understand its unique mechanism of action, develop efficient synthetic routes for its production, and thus enable the generation of analogues for structure-activity relationship studies and optimization of its pharmacological properties. Our review provides a comprehensive treatise on the progress in understanding teixobactin chemistry, structure-activity relationships, and mechanisms of antibacterial activity. Teixobactin represents an exciting starting point for the development of new antibiotics that can be used to combat multidrug-resistant bacterial ("superbug") infections.
© 2019 New York Academy of Sciences.

Entities:  

Keywords:  antimicrobial peptides; antimicrobial resistance; methicillin-resistant Staphylococcus aureus; solid-phase peptide synthesis; structure−activity relationships; teixobactin

Mesh:

Substances:

Year:  2019        PMID: 31792983     DOI: 10.1111/nyas.14282

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Trends in peptide drug discovery.

Authors:  Markus Muttenthaler; Glenn F King; David J Adams; Paul F Alewood
Journal:  Nat Rev Drug Discov       Date:  2021-02-03       Impact factor: 84.694

2.  Antimicrobial Effects of L-Chg10-Teixobactin against Enterococcus faecalis In Vitro.

Authors:  Alaa Jarkhi; Angeline Hui Cheng Lee; Zhenquan Sun; Mingxin Hu; Prasanna Neelakantan; Xuechen Li; Chengfei Zhang
Journal:  Microorganisms       Date:  2022-05-26

3.  De Novo Resistance to Arg10-Teixobactin Occurs Slowly and Is Costly.

Authors:  Daniel G Lloyd; Benjamin J Schofield; Matthew R Goddard; Edward J Taylor
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study.

Authors:  Maytham Hussein; John A Karas; Elena K Schneider-Futschik; Fan Chen; James Swarbrick; Olivia K A Paulin; Daniel Hoyer; Mark Baker; Yan Zhu; Jian Li; Tony Velkov
Journal:  mSystems       Date:  2020-05-26       Impact factor: 6.496

5.  Mode of action of teixobactins in cellular membranes.

Authors:  Rhythm Shukla; João Medeiros-Silva; Anish Parmar; Bram J A Vermeulen; Sanjit Das; Alessandra Lucini Paioni; Shehrazade Jekhmane; Joseph Lorent; Alexandre M J J Bonvin; Marc Baldus; Moreno Lelli; Edwin J A Veldhuizen; Eefjan Breukink; Ishwar Singh; Markus Weingarth
Journal:  Nat Commun       Date:  2020-06-05       Impact factor: 14.919

Review 6.  Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.

Authors:  András Fodor; Birhan Addisie Abate; Péter Deák; László Fodor; Ervin Gyenge; Michael G Klein; Zsuzsanna Koncz; Josephat Muvevi; László Ötvös; Gyöngyi Székely; Dávid Vozik; László Makrai
Journal:  Pathogens       Date:  2020-06-29

Review 7.  Emerging peptide antibiotics with therapeutic potential.

Authors:  Gregory Upert; Anatol Luther; Daniel Obrecht; Philipp Ermert
Journal:  Med Drug Discov       Date:  2020-12-30

8.  Beneficial Impacts of Incorporating the Non-Natural Amino Acid Azulenyl-Alanine into the Trp-Rich Antimicrobial Peptide buCATHL4B.

Authors:  Areetha R D'Souza; Matthew R Necelis; Alona Kulesha; Gregory A Caputo; Olga V Makhlynets
Journal:  Biomolecules       Date:  2021-03-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.